Lars Endahl

Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes

Tim Heise, Leszek Nosek, Birgitte Rønn et al. · Diabetes · 2004 · 618 citations · Full text

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou et al. · Diabetes Care · 2012 · 333 citations · Full text

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato et al. · The Lancet · 2012 · 323 citations

Diabetes Management, Insulin Degludec, Diabetes +7

A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir

Johannes Plank, Manfred Bodenlenz, Frank Sinner et al. · Diabetes Care · 2005 · 272 citations · Full text

Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

Oliver Klein, Jan Lynge, Lars Endahl et al. · Diabetes Obesity and Metabolism · 2006 · 252 citations